Diabetes technology

Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis

J Clin Endocrinol MetabPublished Systematic review and meta-analysis

Authors' conclusion

Automated insulin delivery exhibits favorable glycemic outcomes and safety profiles in older and high-risk individuals with type 1 diabetes, suggesting potential benefits for populations traditionally considered vulnerable, although no significant improvements were observed in psychosocial outcomes.

Study context

Population
Older adults (≥60 years) and high-risk individuals with T1D (impaired awareness of hypoglycaemia, cognitive or functional impairment)
Participants
967 adults23 studies
Comparison
Automated insulin delivery (AID) vs comparator
Outcome
TIR (3.9-10.0 mmol/L [70-180 mg/dL])
Methodological detailsrandom-effects models
  • Random-effects models

Pooled result

As reported in the abstract

TIR

AID increased TIR by

11.38%

95% CI 8.07–14.70; I2 = 70%; P < .0001; equivalent to 2.7 hours/day

Further pooled results

TIR during the day

TIR improvement during the day
8.70% (95% CI 5.18-12.22%)

TIR overnight

TIR improvement overnight
13.35% (95% CI 11.07-15.62%)

Commercial vs noncommercial systems

Favorable improvement comparable among commercial and noncommercial systems

Time in hyperglycaemia

AID reduced time in hyperglycemia
−7.89%

Time in hypoglycaemia

AID reduced time in hypoglycemia
−1.16%

Psychosocial well-being

No significant differences in psychosocial well-being

Safety

DKA and severe hypoglycaemia

DKA and severe hypoglycemia events were not significant

Original publication

Glycemic and psychosocial outcomes of automated insulin delivery in older and high-risk populations with type 1 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. Published 30 September 2026. doi:10.1210/clinem/dgag344

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.